New York, NY / ACCESSWIRE / November 18, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company note on Aethlon Medical, Inc. (AEMD), a medical device company focused on creating innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions. In the note, SeeThruEquity is raising its price target price to $0.74 from $0.52.

"Aethlon Medical's announcement that its Hemopurifier device was used to treat an Ebola patient in Germany is encouraging. We believe the Hemopurifier will be shown to be an advanced, broad-spectrum countermeasure against pandemic threats like Ebola. It is significant that the Chief of Nephrology at Frankfurt University Hospital reported that 242 million Ebola viruses were captured within the Hemopurifier(R) during the treatment, resulting in a 400-fold reduction in viral load. In light of these developments, we are increasing our price target to $0.74 per share," stated Ajay Tandon, Chief Executive Officer of SeeThruEquity.

The note is available here: AEMD Company Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will also be available on these platforms.

Highlights from the note are as follows:

AEMD announces first treatment of an Ebola patient

On Oct 14, 2014, AEMD announced the first use of its Hemopurifier therapy on a patient (WHO doctor who contracted the virus in Sierra Leone) infected with Ebola virus at the Frankfurt University Hospital in Germany. On Nov 14, 2014, data presented at the American Society of Nephrology (ASN) by Helmut Geiger, Chief of Nephrology at Frankfurt University Hospital, showed that the Aethlon Hemopurifier(R) was used in the successful treatment of the critically-ill Ebola-infected patient. At the time of Hemopurifier(R) administration, the Ebola patient was unconscious, suffering from multiple organ failure and had a viral load of 400,000 virus copies per ml of blood. Geiger reported that 242 million Ebola viruses were captured within the Hemopurifier(R) during the treatment, resulting in a 400-fold reduction in viral load. The virus is no longer detectable in the patient's blood and he is expected to make a full recovery. The treatment was well tolerated with no adverse events reported.

As there is no Ebola-specific treatment currently approved, we believe the use of Aethlon's Hemopurifier therapy for Ebola treatment is of great significance in the medical as well as the investment communities, and presents a significant market opportunity for AEMD. The Aethlon Hemopurifier is a first-in-class device that targets the rapid elimination of a broad spectrum of viruses and immunosuppressive proteins from the circulatory system of infected individuals. In the care of Ebola-infected patients too, the Hemopurifier targets the rapid elimination of circulating ebolavirus to inhibit continued progeny virus replication and the direct targeting of shed glycoproteins that overwhelm the host immune response.

Hemopurifier could address emerging pandemic threats

We believe AEMD's Hemopurifier is the most advanced and perhaps the only true broad-spectrum countermeasure against emerging pandemic threats such as Ebola and other viral threats. This is well supported by successful outcomes of Hemopurifier in various in-vitro studies that have verified the device to capture various viruses including Ebola, dengue, lassa, H5N1 avian influenza, 1918 influenza, 2009 H1N1 influenza, West Nile and monkeypox. Specifically related to Ebola virus, previous Hemopurifier studies conducted at The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) showed that the device captured ~50% of both wild type and mutant strains of ZEBOV (Zaire strain of Ebola).

Additionally, the upcoming FDA-approved human feasibility studies of Hemopurifier therapy for HCV in the U.S. will contribute valuable safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C. We believe Hemopurifier has high probability of successfully completing the safety study (administered to ~100 HIV and HCV patients in India without any major safety issues) and gain market clearance for major disease conditions in 2016.

Please review important disclosures on our website at www.seethruequity.com.

About Aethlon Medical, Inc.

Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier(R), a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. Additional information can be found online at www.AethlonMedical.com.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
(646) 495-0939

SOURCE: SeeThruEquity